OR WAIT null SECS
The acquisition will give IDT Biologika access to the veterinary vaccines market.
IDT Biologika announced on Aug. 25, 2015 that it will acquire Gallant Custom Laboratories, Inc., and the acquisition will close on Aug. 31, 2015. According to an IDT press release, Gallant Custom Laboratories is the only Canadian company authorized by the Canadian Food Inspection Agency (CFIA) to manufacture autogenous viral and bacterial vaccines.
“With its strong scientific focus, in-house research and development, and production of autogenous vaccines for the Canadian market, Gallant is an outstanding match for the IDT Group,” said IDT Biologika CEO Ralf Pfirmann, in a press release. Gallant will continue doing business under its name, albeit with a slight addition: It will now be known as “Gallant Customs Laboratories, an IDT Biologika company.”
This deal to purchase Gallant is the second acquisition by IDT in North America in 2015. It follows a transaction for IDT to acquire a manufacturing facility in Rockville, Maryland.
Source: IDT Biologika